Literature DB >> 2573143

Gastric and esophageal acidity during continuous treatment with H2-antagonists in uncomplicated esophagitis.

S Fiorucci1, L Santucci, E Perrone, F Abbritti, A Morelli.   

Abstract

Twenty-four-hour gastric and esophageal pH were monitored simultaneously in 19 patients with moderate esophagitis before and after a randomized crossover treatment with 40 mg famotidine or 300 mg ranitidine. Gastroesophageal reflux in patients with esophagitis was compared with that in 22 healthy controls. Patients with esophagitis had more esophageal acidity than controls; the percentage of time with esophageal pH less than 4 was significantly greater during a 24-h period (p less than 0.01) both in the upright (p less than 0.01) and in the supine (p less than 0.01) position. In esophagitis patients the percentage of time with pH less than 4 during the total 24-h period correlated closely with acid reflux in the upright (p less than 0.001) and supine (p less than 0.01) position. This indicates that daytime reflux is probably as injurious to the esophagus as nighttime reflux. Famotidine and ranitidine decreased gastric acidity during the entire 24-h period (p less than 0.001) but not during the daytime or early evening. The inhibitory effect lasted slightly longer with famotidine (12 h) than with ranitidine (10 h). Famotidine and ranitidine reduced esophageal acidity during the entire 24-h period (p less than 0.001) and particularly during the nighttime (p less than 0.001) but not during the daytime. Famotidine and ranitidine also did not modify the esophageal acid clearance. Nightly doses of famotidine or ranitidine were ineffective in reducing GER during daytime hours.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2573143     DOI: 10.3109/00365528909093107

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  4 in total

1.  Oesophageal pH monitoring.

Authors:  R Stewart
Journal:  Ir J Med Sci       Date:  1991-02       Impact factor: 1.568

2.  Efficacy of famotidine 20 mg twice a day versus 40 mg twice a day in the treatment of erosive or ulcerative reflux esophagitis.

Authors:  I C Wesdorp; W Dekker; H P Festen
Journal:  Dig Dis Sci       Date:  1993-12       Impact factor: 3.199

3.  Pharmacokinetics and pharmacodynamics of famotidine in patients with reflux oesophagitis.

Authors:  U Gladziwa; S Wagner; K V Dakshinamurty; E el Desoky; B Dreuw; U Klotz
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

Review 4.  pH, healing rate, and symptom relief in patients with GERD.

Authors:  J Q Huang; R H Hunt
Journal:  Yale J Biol Med       Date:  1999 Mar-Jun
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.